It is hard to get excited after looking at Becton Dickinson's (NYSE:BDX) recent performance, when its stock has declined 24% over the past three months. We, however decided to study the company's ...

Fong replaced Brad Lerman as Medtronic’s GC, who retired in 2022 before being lured out of retirement to become CLO at ...

Medtronic is bringing on a medical device industry veteran for its new top lawyer as it prepares for a major organizational ...

We came across a bullish thesis on Becton, Dickinson and Company on Disruptive Analytics’ Substack by Magnus Ofstad. In this ...

This was the stock's second consecutive day of gains.

According to the Adhishthana Principles, a stock begins forming its Cakra from Phase 4, with the formation typically ...

Intraosseous Infusion Devices revenue is expected to grow by CAGR 6.2% from 2025 to 2032 and reach nearly USD 8.79 Bn. In 2032. From ER to EMS, intraosseous infusion is changing how we deliver urgent ...

To enable awareness and knowledge-sharing around best practices of atherothrombectomy in the treatment of vascular diseases a ...

Ivan Fong, 63, was one of the highest-proifile GCs to sign an amicus brief supporting Perkins Coie's legal challenge of ...

Review the current Becton Dickinson & Co (BDX:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if BDX is the best investment for you.